<DOC>
	<DOCNO>NCT00240916</DOCNO>
	<brief_summary>This immunogenicity study evaluate development immune response healthy infant follow primary vaccination Attenuvax 6 9 month age compare responses 12 month-old infant receive MMR-II . Responses infant receive early two dose measles vaccine regimen first dose give 6 9 month follow second dose administer 12 month also compare infant give single dose 12 month age ( Table 2 ) . The current approved regimen measles vaccination first vaccination 12-15 month subsequent vaccination school entry . A secondary endpoint study assess safety measles vaccine administer Attenuvax 6 9 month age early two dose measles vaccine regimen Attenuvax administer 6 9 month follow MMR-II 12 month age .</brief_summary>
	<brief_title>Ontogeny Measles Immunity Infants</brief_title>
	<detailed_description>This open-label immunogenicity safety study live attenuate Measles Vaccine ( Attenuvax ) Measles-Mumps-Rubella ( MMR-II ) vaccine administer healthy child 6 ( n=70 ) , 9 ( n=70 ) , 12 ( n=70 ) month age . Attenuvax ( Measles Virus Vaccine Live , Merck &amp; Co. , Inc ) MMR-II ( Measles-Mumps-Rubella Virus Vaccine Live , Merck &amp; Co. , Inc ) deliver 0.5 mL per dose , administer subcutaneously . Both vaccine license use infant United States . MMR-II recommend part childhood immunization schedule AAP ACIP , Attenuvax recommend use single component vaccine infant 6-11 month particularly foreign travel measles outbreaks79 . Infants vaccinate Attenuvax 6 9 month receive MMR-II 12 month age recommend follow-up vaccination . Immunization measles give trivalent formulation mumps rubella indicate primary dose 12-15 month age second dose recommend routinely time school entry , 4-6 year age , give early age provide interval first second dos least 4 week . Two hundred ten healthy child attend Palo Alto Medical Clinic recruit one three cohort five year period . ( Table 1 ) . All child cohort 1 2 ( 6 9 month old infant ) receive Attenuvax part participation study follow MMR-II 12 month age part routine WCC study vaccine . Infants recruit cohort 3 , ( twelve month old infant ) receive one dose MMR-II 12 month . All infant study ( cohort 1 , 2 3 ) receive MMR-II 12 month part routine childhood vaccine . The vaccination schedule summarize Table 1 . Other immunization require routine WCC administer simultaneously . Participation entail 2-4 visit , 2-3 blood sample , 1-2 immunization end 9-18 month visit , total 3 12 month time participation subject depend cohort participant opt second follow-up blood sample .</detailed_description>
	<mesh_term>Measles</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects must meet follow criterion order enrol : 1 . Healthy infant 6 , 9 , 12 month ( + 3 week ) age 2 . Free obvious health problem establish medical history clinical examination enter study 3 . Parent/legal guardian willing capable signing write informed consent 4 . Parent/legal guardian expect available entire study 5 . Parent/legal guardian reach telephone All subject meet follow exclusion criterion baseline exclude study participation : 1 . Former premature infant ( &lt; 36 week ) 2 . Birth weight &lt; 2500grams 3 . Significant underlying chronic illness 4 . Immunodeficiency disease immunosuppressive therapy participant 5 . Any condition clinical judgment investigator might interfere vaccine evaluation 6 . Allergy component vaccine , include anaphylaxis anyphalaxoid reaction neomycin egg 7 . Administration investigational drug 8 . Blood product within 3 month initial enrollment 9 . Current febrile respiratory illness active febrile infection 10 . Family history congenital/hereditary immunodeficiency , unless immune competence subject determine . 11 . Blood dyscrasia , leukemia , lymphoma type malignant neoplasm affect bone marrow lymphatic system .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>